Hospital-acquired pneumonia (HAP) remains a critical ICU threat. Traditionally viewed through a rigid lens, HAP definitions have evolved due to new insights into microbial dynamics.
Clinicians now see HAP as part of a spectrum, from tracheobronchitis to severe cases. New diagnostic tools like PCR, NGS, and biomarkers like procalcitonin promise faster and more precise treatments.
Looking forward, the integration of AI and precision medicine may redefine how HAP is managed.